Efficacy and safety of micafungin in empiric and D-index-guided early antifungal therapy for febrile neutropenia; A subgroup analysis of the CEDMIC trial

Micafungin has been widely used as empiric or preemptive antifungal therapy during neutropenia in Japan (Kimura et al., 2020). This is partly because micafungin was the only available echinocandin agent until caspofungin was launched in 2012. Previous randomized controlled trials and prospective single-arm studies showed that the use of micafungin in empiric antifungal therapy offered comparable efficacy and better safety compared with other classes of mold active agents (Jeong et al., 2016, Oyake et al., 2016, Park et al., 2010, Tamura et al., 2009, Yamaguchi et al., 2011, Yoshida et al., 2012).

Source: International Journal of Infectious Diseases - September 2, 2020 Category: Infectious Diseases Authors: Shun-ichi Kimura, Yoshinobu Kanda, Masaki Iino, Takahiro Fukuda, Emiko Sakaida, Tatsuo Oyake, Hiroki Yamaguchi, Shin-ichiro Fujiwara, Yumi Jo, Akinao Okamoto, Hiroyuki Fujita, Yasushi Takamatsu, Yoshio Saburi, Itaru Matsumura, Jun Yamanouchi, Souichi Shir Source Type: research